Craig J. Canfield

TL;DR: A rapid, semiautomated microdilution method was developed for measuring the activity of potential antimalarial drugs against cultured intraerythrocytic asexual forms of the human malaria parasite Plasmodium falciparum, and results demonstrated that the method is sensitive and precise.

TL;DR: Of the 104 patients with falciparum malaria treated with atovaquone plus proguanil for 3-7 days, 101 were cured and had virtually no adverse side effects, but parasitemia recurred in most patients.

TL;DR: Treatment with atovaquone and proguanil hydrochloride was significantly more effective than mefloquine (Thailand), amodiaquine (Gabon), chloroquine(Peru and the Philippines) or chloroquines plus pyrimethamine/sulfadoxine (Philippines), in clinical trials where the comparator drug was highly effective.

TL;DR: Oral administration of this new drug should circumvent the shortcomings and retain the advantages found with both proguanil and WR99210, and represent a new antifolate class of drugs that the authors have named oxyguanils or hydroxylamine-derived biguanides.

TL;DR: The kinetics of mefloquine hydrochloride were studied in 20 healthy adult male subjects after single oral doses of 250, 500, 1,000, and 1,500 mg, and it is anticipated that occasional treatment failures may occur when the drug is used for single‐dose therapy on a large scale.